Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public

Added by lklinares
Group name EquipeLL
Item Type Journal Article
Title FOXO3a and the MAPK p38 are activated by cetuximab to induce cell death and inhibit cell proliferation and their expression predicts cetuximab efficacy in colorectal cancer
Creator Marzi et al.
Author L. Marzi
Author E. Combes
Author A. Ayrolles-Torro
Author D. Tosi
Author D. Desigaud
Author E. Perez-Gracia
Author C. Larbouret
Author C. Montagut
Author M. Iglesias
Author M. Jarlier
Author V. Denis
Author L. K. Linares
Author E. W.-F. Lam
Author P. Martineau
Author M. Del Rio
Author C. Gongora
Abstract BACKGROUND: Cetuximab, a monoclonal antibody against EGFR used for the treatment of colorectal cancer (CRC), is ineffective in many patients. The aim of this study was to identify the signalling pathways activated by cetuximab in CRC cells and define new biomarker of response. METHODS: We used in vitro, in vivo models and clinical CRC samples to assess the role of p38 and FOXO3a in cetuximab mechanism of action. RESULTS: We show that cetuximab activates the MAPK p38. Specifically, p38 inhibition reduced cetuximab efficacy on cell growth and cell death. At the molecular level, cetuximab activates the transcription factor FOXO3a and promotes its nuclear translocation via p38-mediated phosphorylation, leading to the upregulation of its target genes p27 and BIM and the subsequent induction of apoptosis and inhibition of cell proliferation. Finally, we found that high FOXO3a and p38 expression levels are associated with better response rate and improved outcome in cetuximab-treated patients with CRC harbouring WT KRAS. CONCLUSIONS: We identify FOXO3a as a key mediator of cetuximab mechanism of action in CRC cells and define p38 as its activator in this context. Moreover, high FOXO3a and p38 expression could predict the response to cetuximab in patients with CRC harbouring WT KRAS.
Publication British Journal of Cancer
Volume 115
Issue 10
Pages 1223-1233
Date Nov 08, 2016
Journal Abbr Br J Cancer
Language eng
DOI 10.1038/bjc.2016.313
ISSN 1532-1827
Library Catalog PubMed
Extra PMID: 27685445 PMCID: PMC5104890
Tags Animals, Antibodies, Monoclonal, Antineoplastic Agents, Caco-2 Cells, Cell Death, Cell Line, Tumor, Cell Proliferation, Cetuximab, Colorectal Neoplasms, ErbB Receptors, Female, Forkhead Box Protein O3, Gene Expression Regulation, Neoplastic, Humans, Mice, Mice, Nude, original, p38 Mitogen-Activated Protein Kinases, ras Proteins, Signal Transduction, Up-Regulation
Date Added 2024/12/03 - 09:12:56
Date Modified 2024/12/03 - 09:12:56
Notes and Attachments PubMed entry (Attachment)
Texte intégral (Attachment)


© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés